ACTRN12623000397617招募中2 期
Change in Anti-Influenza Antibody Level following Temporary Withholding of Immunosuppressant in Rheumatic diseases and Lupus (TWIRL) Study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients with systemic lupus erythematosus, who are currently enrolled in the Australian Lupus Registry & Biobank.
- •Receiving stable doses of mycophenolate and have not experienced a flare in the last 3 months.
- •Combination with hydroxychloroquine will be permitted
- •Prednisolone must be at a dose equal or lower than 7.5mg/day.
排除标准
- •Concomitant use of other biologics such as rituximab or belimumab in the last 6 months
- •Other targeted synthetic disease modifying anti-rheumatic drugs such as JAK inhibitors
- •Age >65 as a different, adjuvated vaccine is clinically recommended for this age group
研究者
相似试验
已完成
不适用
Study of the antibody titer by Influenza vaccination in Rheumatoid Arthritis patients treated with MTX and Biological agentsRheumatoid ArthritisJPRN-UMIN000010405agoya Medical Center, National Hospital Organization in JAPA170
已完成
Unknown
Changes in specific antibody titers and interferon gamma levels after a BNT162b2 vaccine boosterCOVID-19JPRN-UMIN000048810Fukuoka City Hospital400
已完成
不适用
Changes in specific antibody titers and interferon gamma levels after an Omicron BA.4/BA.5-Adapted Bivalent BoosterCOVID-19JPRN-UMIN000049273Fukuoka City Hospital150
进行中（未招募）
1 期
Evaluation of how body's defense system against infection responds to the flu vaccine in cancer patients being treated with idelalisibTo assess the immune response to an influenza vaccine in subjects with B-cell malignancies treated with idelalisibMedDRA version: 20.0 Level: PT Classification code 10065856 Term: Non-Hodgkin's lymphoma unspecified histology indolent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003055-30-ESGilead Sciences, Inc.22
进行中（未招募）
1 期
Evaluation of how body's defense system against infection responds to the flu vaccine in cancer patients being treated with idelalisibTo assess the immune response to an influenza vaccine in subjects with B-cell malignancies treated with idelalisibMedDRA version: 20.0 Level: PT Classification code 10065856 Term: Non-Hodgkin's lymphoma unspecified histology indolent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003055-30-CZGilead Sciences, Inc.22